Drug Profile
Atomoxetine - Eli Lilly and Company
Alternative Names: Atomoxetine hydrochloride; LY 139603; Strattera; Tomoxetine; Tomoxetine hydrochlorideLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Johns Hopkins University
- Class Antidementias; Antidepressants; Antiparkinsonians; Behavioural disorder therapies; Propylamines
- Mechanism of Action Adrenergic uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder
- Discontinued Alzheimer's disease; Major depressive disorder; Parkinson's disease
Most Recent Events
- 06 Jan 2020 Discontinued - Phase-III for Parkinson's disease in USA (PO) (Eli Lilly and Company website, January 2020)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Attention-deficit-hyperactivity-disorder(In volunteers) in Japan (PO, Liquid)
- 07 Aug 2015 No recent reports on development identified - Phase-III for Attention-deficit hyperactivity disorder (In adults) in China (PO)